{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:00:54Z","timestamp":1791126054332,"version":"4.1.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T00:00:00Z","timestamp":1268697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1038\/nrneph.2010.30","type":"journal-article","created":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T12:29:32Z","timestamp":1268742572000},"page":"261-273","source":"Crossref","is-referenced-by-count":290,"title":["Aldosterone: effects on the kidney and cardiovascular system"],"prefix":"10.1038","volume":"6","author":[{"given":"Marie","family":"Briet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto L.","family":"Schiffrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,16]]},"reference":[{"key":"BFnrneph201030_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00424-009-0656-0","volume":"458","author":"J Loffing","year":"2009","unstructured":"Loffing, J. & Korbmacher, C. Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC). Pflugers Arch. 458, 111\u2013135 (2009).","journal-title":"Pflugers Arch."},{"key":"BFnrneph201030_CR2","doi-asserted-by":"publisher","first-page":"F714","DOI":"10.1152\/ajprenal.00061.2006","volume":"291","author":"V Bhalla","year":"2006","unstructured":"Bhalla, V., Soundararajan, R., Pao, A. C., Li, H. & Pearce, D. Disinhibitory pathways for control of sodium transport: regulation of ENaC by SGK1 and GILZ. Am. J. Physiol. Renal Physiol. 291, F714\u2013F721 (2006).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph201030_CR3","doi-asserted-by":"publisher","first-page":"17434","DOI":"10.1073\/pnas.0408146101","volume":"101","author":"A N\u00e1ray-Fejes-T\u00f3th","year":"2004","unstructured":"N\u00e1ray-Fejes-T\u00f3th, A., Snyder, P. M. & Fejes-T\u00f3th, G. The kidney-specific WNK1 isoform is induced by aldosterone and stimulates epithelial sodium channel-mediated Na+ transport. Proc. Natl Acad. Sci. USA 101, 17434\u201317439 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph201030_CR4","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1172\/JCI38323","volume":"119","author":"DJ Rozansky","year":"2009","unstructured":"Rozansky, D. J. et al. Aldosterone mediates activation of the thiazide-sensitive Na-Cl cotransporter through an SGK1 and WNK4 signaling pathway. J. Clin. Invest. 119, 2601\u20132612 (2009).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201030_CR5","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1172\/JCI118867","volume":"98","author":"EL Greene","year":"1996","unstructured":"Greene, E. L., Kren, S. & Hostetter, T. H. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 98, 1063\u20131068 (1996).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201030_CR6","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1172\/JCI117269","volume":"93","author":"M Young","year":"1994","unstructured":"Young, M., Fullerton, M., Dilley, R. & Funder, J. Mineralocorticoids, hypertension, and cardiac fibrosis. J. Clin. Invest. 93, 2578\u20132583 (1994).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201030_CR7","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi, E. R. et al. Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 63, 1791\u20131800 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph201030_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.HYP.0000118519.66430.22","volume":"43","author":"A Nishiyama","year":"2004","unstructured":"Nishiyama, A. et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt-induced hypertensive rats. Hypertension 43, 841\u2013848 (2004).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR9","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1210\/endo-125-4-2224","volume":"125","author":"JW Funder","year":"1989","unstructured":"Funder, J. W., Pearce, P. T., Smith, R. & Campbell, J. Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 125, 2224\u20132226 (1989).","journal-title":"Endocrinology"},{"key":"BFnrneph201030_CR10","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1161\/CIRCRESAHA.108.174235","volume":"102","author":"M Caprio","year":"2008","unstructured":"Caprio, M. et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ. Res. 102, 1359\u20131367 (2008).","journal-title":"Circ. Res."},{"key":"BFnrneph201030_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1161\/01.RES.71.3.503","volume":"71","author":"M Lomb\u00e8s","year":"1992","unstructured":"Lomb\u00e8s, M. et al. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ. Res. 71, 503\u2013510 (1992).","journal-title":"Circ. Res."},{"key":"BFnrneph201030_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","volume":"96","author":"IZ Jaffe","year":"2005","unstructured":"Jaffe, I. Z. & Mendelsohn, M. E. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ. Res. 96, 643\u2013650 (2005).","journal-title":"Circ. Res."},{"key":"BFnrneph201030_CR13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","volume":"45","author":"A Nishiyama","year":"2005","unstructured":"Nishiyama, A. et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 45, 710\u2013716 (2005).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR14","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1096\/fj.05-4642fje","volume":"20","author":"S Johar","year":"2006","unstructured":"Johar, S., Cave, A. C., Narayanapanicker, A., Grieve, D. J. & Shah, A. M. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 20, 1546\u20131548 (2006).","journal-title":"FASEB J."},{"key":"BFnrneph201030_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","volume":"33","author":"R Rocha","year":"1999","unstructured":"Rocha, R., Chander, P. N., Zuckerman, A. & Stier, C. T. Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33, 232\u2013237 (1999).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR16","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309\u20131321 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201030_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709\u2013717 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201030_CR18","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/sj.ki.5000201","volume":"69","author":"J Ma","year":"2006","unstructured":"Ma, J. et al. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int. 69, 1064\u20131072 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph201030_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","volume":"49","author":"S Shibata","year":"2007","unstructured":"Shibata, S., Nagase, M., Yoshida, S., Kawachi, H. & Fujita, T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 49, 355\u2013364 (2007).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR20","doi-asserted-by":"publisher","first-page":"F802","DOI":"10.1152\/ajprenal.00197.2009","volume":"297","author":"J Du","year":"2009","unstructured":"Du, J. et al. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats. Am. J. Physiol. Renal Physiol. 297, F802\u2013F808 (2009).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph201030_CR21","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1681\/ASN.2004090804","volume":"16","author":"JC Aldigier","year":"2005","unstructured":"Aldigier, J. C., Kanjanbuch, T., Ma, L. J., Brown, N. J. & Fogo, A. B. Regression of existing glomerulosclerosis by inhibition of aldosterone. J. Am. Soc. Nephrol. 16, 3306\u20133314 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201030_CR22","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","volume":"66","author":"G Fujisawa","year":"2004","unstructured":"Fujisawa, G. et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int. 66, 1493\u20131502 (2004).","journal-title":"Kidney Int."},{"key":"BFnrneph201030_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/ki.2008.507","volume":"75","author":"H Ikeda","year":"2009","unstructured":"Ikeda, H. et al. Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. Kidney Int. 75, 147\u2013155 (2009).","journal-title":"Kidney Int."},{"key":"BFnrneph201030_CR24","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1113\/expphysiol.2008.042085","volume":"93","author":"HM Siragy","year":"2008","unstructured":"Siragy, H. M. & Xue, C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp. Physiol. 93, 817\u2013824 (2008).","journal-title":"Exp. Physiol."},{"key":"BFnrneph201030_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1681\/ASN.2007050531","volume":"19","author":"Y Terada","year":"2008","unstructured":"Terada, Y. et al. Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium. J. Am. Soc. Nephrol. 19, 298\u2013309 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201030_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0002-9440(10)63938-7","volume":"158","author":"BL Riser","year":"2001","unstructured":"Riser, B. L. et al. Cyclic stretching of mesangial cells up-regulates intercellular adhesion molecule-1 and leukocyte adherence: a possible new mechanism for glomerulosclerosis. Am. J. Pathol. 158, 11\u201317 (2001).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph201030_CR27","doi-asserted-by":"publisher","first-page":"F1323","DOI":"10.1152\/ajprenal.90428.2008","volume":"296","author":"S Huang","year":"2009","unstructured":"Huang, S., Zhang, A., Ding, G. & Chen, R. Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation. Am. J. Physiol. Renal Physiol. 296, F1323\u2013F1333 (2009).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph201030_CR28","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1161\/01.HYP.0000034738.79310.06","volume":"40","author":"A Virdis","year":"2002","unstructured":"Virdis, A. et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40, 504\u2013510 (2002).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR29","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1161\/hy1101.093423","volume":"38","author":"RA Beswick","year":"2001","unstructured":"Beswick, R. A., Dorrance, A. M., Leite, R. & Webb, R. C. NADH\/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 38, 1107\u20131111 (2001).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR30","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/ndt\/gfl780","volume":"22","author":"ML Onozato","year":"2007","unstructured":"Onozato, M. L. et al. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol. Dial. Transplant. 22, 1314\u20131322 (2007).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201030_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1161\/01.HYP.37.2.781","volume":"37","author":"RA Beswick","year":"2001","unstructured":"Beswick, R. A. et al. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 37, 781\u2013786 (2001).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR32","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/01.HYP.0000174593.88899.68","volume":"46","author":"Y Nagai","year":"2005","unstructured":"Nagai, Y. et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1\/2 in rat renal fibroblasts. Hypertension 46, 1039\u20131045 (2005).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR33","doi-asserted-by":"publisher","first-page":"F723","DOI":"10.1152\/ajprenal.00480.2006","volume":"293","author":"A Zhang","year":"2007","unstructured":"Zhang, A., Jia, Z., Guo, X. & Yang, T. Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. Am. J. Physiol. Renal Physiol. 293, F723\u2013F731 (2007).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph201030_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbrc.2006.07.057","volume":"348","author":"L Lai","year":"2006","unstructured":"Lai, L., Chen, J., Hao, C. M., Lin, S. & Gu, Y. Aldosterone promotes fibronectin production through a Smad2-dependent TGF-beta1 pathway in mesangial cells. Biochem. Biophys. Res. Commun. 348, 70\u201375 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrneph201030_CR35","doi-asserted-by":"publisher","first-page":"E305","DOI":"10.1152\/ajpendo.00512.2007","volume":"295","author":"TY Chun","year":"2008","unstructured":"Chun, T. Y., Chander, P. N., Kim, J. W., Pratt, J. H. & Stier, C. T. Jr. Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats. Am. J. Physiol. Endocrinol. Metab. 295, E305\u2013E312 (2008).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFnrneph201030_CR36","doi-asserted-by":"publisher","first-page":"F1059","DOI":"10.1152\/ajprenal.00202.2003","volume":"286","author":"I Juknevicius","year":"2004","unstructured":"Juknevicius, I., Segal, Y., Kren, S., Lee, R. & Hostetter, T. H. Effect of aldosterone on renal transforming growth factor-beta. Am. J. Physiol. Renal Physiol. 286, F1059\u2013F1062 (2004).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph201030_CR37","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1161\/01.HYP.35.5.1078","volume":"35","author":"Y Sun","year":"2000","unstructured":"Sun, Y., Zhang, J., Zhang, J. Q. & Ramires, F. J. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 35, 1078\u20131084 (2000).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/sj.ki.5000438","volume":"70","author":"KH Han","year":"2006","unstructured":"Han, K. H. et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int. 70, 111\u2013120 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph201030_CR39","first-page":"180","volume":"40","author":"J Yuan","year":"2007","unstructured":"Yuan, J., Jia, R. & Bao, Y. Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells. J. Biochem. Mol. Biol. 40, 180\u2013188 (2007).","journal-title":"J. Biochem. Mol. Biol."},{"key":"BFnrneph201030_CR40","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","volume":"58","author":"NJ Brown","year":"2000","unstructured":"Brown, N. J. et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 58, 1219\u20131227 (2000).","journal-title":"Kidney Int."},{"key":"BFnrneph201030_CR41","doi-asserted-by":"publisher","first-page":"F1287","DOI":"10.1152\/ajprenal.00017.2008","volume":"294","author":"W Huang","year":"2008","unstructured":"Huang, W. et al. Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. Am. J. Physiol. Renal Physiol. 294, F1287\u2013F1295 (2008).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph201030_CR42","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.tips.2007.04.006","volume":"28","author":"H Shimokawa","year":"2007","unstructured":"Shimokawa, H. & Rashid, M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol. Sci. 28, 296\u2013302 (2007).","journal-title":"Trends Pharmacol. Sci."},{"key":"BFnrneph201030_CR43","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1681\/ASN.2005121375","volume":"17","author":"GP Sun","year":"2006","unstructured":"Sun, G. P. et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J. Am. Soc. Nephrol. 17, 2193\u20132201 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201030_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF00230355","volume":"425","author":"M Kretzler","year":"1994","unstructured":"Kretzler, M., Koeppen-Hagemann, I. & Kriz, W. Podocyte damage is a critical step in the development of glomerulosclerosis in the uninephrectomised-desoxycorticosterone hypertensive rat. Virchows Arch. 425, 181\u2013193 (1994).","journal-title":"Virchows Arch."},{"key":"BFnrneph201030_CR45","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","volume":"47","author":"M Nagase","year":"2006","unstructured":"Nagase, M. et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47, 1084\u20131093 (2006).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR46","doi-asserted-by":"publisher","first-page":"F1013","DOI":"10.1152\/ajprenal.90646.2008","volume":"296","author":"A Whaley-Connell","year":"2009","unstructured":"Whaley-Connell, A. et al. Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am. J. Physiol. Renal Physiol. 296, F1013\u2013F1022 (2009).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph201030_CR47","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","volume":"49","author":"S Shibata","year":"2007","unstructured":"Shibata, S., Nagase, M., Yoshida, S., Kawachi, H. & Fujita, T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 49, 355\u2013364 (2007).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR48","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1161\/HYPERTENSIONAHA.107.091058","volume":"50","author":"M Nagase","year":"2007","unstructured":"Nagase, M., Matsui, H., Shibata, S., Gotoda, T. & Fujita, T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 50, 877\u2013883 (2007).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR49","doi-asserted-by":"publisher","first-page":"F1381","DOI":"10.1152\/ajprenal.00101.2009","volume":"297","author":"SH Lee","year":"2009","unstructured":"Lee, S. H. et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am. J. Physiol. Renal Physiol. 297, F1381\u2013F1390 (2009).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph201030_CR50","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/nm.1879","volume":"14","author":"S Shibata","year":"2008","unstructured":"Shibata, S. et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat. Med. 14, 1370\u20131376 (2008).","journal-title":"Nat. Med."},{"key":"BFnrneph201030_CR51","doi-asserted-by":"publisher","first-page":"F1513","DOI":"10.1152\/ajprenal.00402.2006","volume":"292","author":"H Otani","year":"2007","unstructured":"Otani, H. et al. Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation. Am. J. Physiol. Renal Physiol. 292, F1513\u2013F1525 (2007).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph201030_CR52","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1681\/ASN.2005020129","volume":"16","author":"Y Terada","year":"2005","unstructured":"Terada, Y. et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1\/2, cyclin D1, and cyclin A. J. Am. Soc. Nephrol. 16, 2296\u20132305 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201030_CR53","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0140-6736(09)61378-7","volume":"374","author":"CE Jackson","year":"2009","unstructured":"Jackson, C. E. et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 374, 543\u2013550 (2009).","journal-title":"Lancet"},{"key":"BFnrneph201030_CR54","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.amjcard.2008.06.035","volume":"102","author":"N Mercado","year":"2008","unstructured":"Mercado, N. et al. Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial). Am. J. Cardiol. 102, 1151\u20131155 (2008).","journal-title":"Am. J. Cardiol."},{"key":"BFnrneph201030_CR55","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/aje\/kwn209","volume":"168","author":"HJ Lambers Heerspink","year":"2008","unstructured":"Lambers Heerspink, H. J. et al. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am. J. Epidemiol. 168, 897\u2013905 (2008).","journal-title":"Am. J. Epidemiol."},{"key":"BFnrneph201030_CR56","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1681\/ASN.2007101065","volume":"19","author":"AH Brantsma","year":"2008","unstructured":"Brantsma, A. H., Bakker, S. J., de Zeeuw, D., de Jong, P. E. & Gansevoort, R. T. Extended prognostic value of urinary albumin excretion for cardiovascular events. J. Am. Soc. Nephrol. 19, 1785\u20131791 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201030_CR57","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1681\/ASN.2006050445","volume":"18","author":"WB Eijkelkamp","year":"2007","unstructured":"Eijkelkamp, W. B. et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J. Am. Soc. Nephrol. 18, 1540\u20131546 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201030_CR58","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJMoa0902066","volume":"361","author":"E W\u00fchl","year":"2009","unstructured":"W\u00fchl, E. et al. Strict blood-pressure control and progression of renal failure in children. N. Engl. J. Med. 361, 1639\u20131650 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201030_CR59","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1681\/ASN.V9112096","volume":"9","author":"P Ruggenenti","year":"1998","unstructured":"Ruggenenti, P., Perna, A., Benini, R. & Remuzzi, G. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J. Am. Soc. Nephrol. 9, 2096\u20132101 (1998).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201030_CR60","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456\u20131462 (1993).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201030_CR61","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio, G. et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 334, 939\u2013945 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201030_CR62","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","volume":"352","author":"P Ruggenenti","year":"1998","unstructured":"Ruggenenti, P. et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352, 1252\u20131256 (1998).","journal-title":"Lancet"},{"key":"BFnrneph201030_CR63","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861\u2013869 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201030_CR64","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"S Bianchi","year":"2006","unstructured":"Bianchi, S., Bigazzi, R. & Campese, V. M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 70, 2116\u20132123 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph201030_CR65","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","volume":"24","author":"AH van den Meiracker","year":"2006","unstructured":"van den Meiracker, A. H. et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J. Hypertens. 24, 2285\u20132292 (2006).","journal-title":"J. Hypertens."},{"key":"BFnrneph201030_CR66","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","volume":"68","author":"KJ Schjoedt","year":"2005","unstructured":"Schjoedt, K. J. et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 68, 2829\u20132836 (2005).","journal-title":"Kidney Int."},{"key":"BFnrneph201030_CR67","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","volume":"28","author":"K Rossing","year":"2005","unstructured":"Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F. & Parving, H. H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28, 2106\u20132112 (2005).","journal-title":"Diabetes Care"},{"key":"BFnrneph201030_CR68","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"A Chrysostomou","year":"2006","unstructured":"Chrysostomou, A., Pedagogos, E., MacGregor, L. & Becker, G. J. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin. J. Am. Soc. Nephrol. 1, 256\u2013262 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201030_CR69","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/sj.ki.5001580","volume":"70","author":"KJ Schjoedt","year":"2006","unstructured":"Schjoedt, K. J. et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 70, 536\u2013542 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph201030_CR70","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein, M. et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 1, 940\u2013951 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201030_CR71","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1291\/hypres.31.59","volume":"31","author":"Y Furumatsu","year":"2008","unstructured":"Furumatsu, Y. et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens. Res. 31, 59\u201367 (2008).","journal-title":"Hypertens. Res."},{"key":"BFnrneph201030_CR72","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","volume":"52","author":"L Tylicki","year":"2008","unstructured":"Tylicki, L. et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am. J. Kidney Dis. 52, 486\u2013493 (2008).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201030_CR73","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","volume":"54","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am. J. Kidney Dis. 54, 205\u2013226 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201030_CR74","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2008.03.013","volume":"51","author":"D de Zeeuw","year":"2008","unstructured":"de Zeeuw, D. Targeting proteinuria as a valid surrogate for individualized kidney protective therapy. Am. J. Kidney Dis. 51, 713\u2013716 (2008).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201030_CR75","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ncpneph1004","volume":"5","author":"AS Bomback","year":"2009","unstructured":"Bomback, A. S., Kshirsagar, A. V. & Klemmer, P. J. Renal aspirin: will all patients with chronic kidney disease one day take spironolactone? Nat. Clin. Pract. Nephrol. 5, 74\u201375 (2009).","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"BFnrneph201030_CR76","first-page":"893","volume":"120","author":"CG Brilla","year":"1992","unstructured":"Brilla, C. G. & Weber, K. T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 120, 893\u2013901 (1992).","journal-title":"J. Lab. Clin. Med."},{"key":"BFnrneph201030_CR77","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0735-1097(00)01129-3","volume":"37","author":"P Lacolley","year":"2001","unstructured":"Lacolley, P. et al. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J. Am. Coll. Cardiol. 37, 662\u2013667 (2001).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrneph201030_CR78","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1161\/01.ATV.17.6.1152","volume":"17","author":"A Benetos","year":"1997","unstructured":"Benetos, A., Lacolley, P. & Safar, M. E. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler. Thromb. Vasc. Biol. 17, 1152\u20131156 (1997).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrneph201030_CR79","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.HYP.28.5.785","volume":"28","author":"D Rizzoni","year":"1996","unstructured":"Rizzoni, D. et al. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 28, 785\u2013790 (1996).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR80","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1161\/01.HYP.0000154365.30593.d3","volume":"45","author":"GE Callera","year":"2005","unstructured":"Callera, G. E. et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 45, 773\u2013779 (2005).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR81","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1210\/en.2007-0864","volume":"149","author":"F Iwashima","year":"2008","unstructured":"Iwashima, F. et al. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 149, 1009\u20131014 (2008).","journal-title":"Endocrinology"},{"key":"BFnrneph201030_CR82","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0002-9440(10)64454-9","volume":"161","author":"Y Sun","year":"2002","unstructured":"Sun, Y. et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am. J. Pathol. 161, 1773\u20131781 (2002).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph201030_CR83","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1291\/hypres.31.363","volume":"31","author":"H Hayashi","year":"2008","unstructured":"Hayashi, H. et al. Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens. Res. 31, 363\u2013375 (2008).","journal-title":"Hypertens. Res."},{"key":"BFnrneph201030_CR84","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1089\/ars.2006.8.1473","volume":"8","author":"A Petry","year":"2006","unstructured":"Petry, A. et al. NOX2 and NOX4 mediate proliferative response in endothelial cells. Antioxid. Redox Signal. 8, 1473\u20131484 (2006).","journal-title":"Antioxid. Redox Signal."},{"key":"BFnrneph201030_CR85","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1210\/en.2006-1691","volume":"148","author":"S Stas","year":"2007","unstructured":"Stas, S. et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 148, 3773\u20133780 (2007).","journal-title":"Endocrinology"},{"key":"BFnrneph201030_CR86","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1291\/hypres.28.925","volume":"28","author":"S Nakano","year":"2005","unstructured":"Nakano, S., Kobayashi, N., Yoshida, K., Ohno, T. & Matsuoka, H. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme\/epidermal growth factor receptor\/extracellular signal-regulated kinases, NAD(P)H oxidase\/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone\/salt-induced hypertensive rats. Hypertens. Res. 28, 925\u2013936 (2005).","journal-title":"Hypertens. Res."},{"key":"BFnrneph201030_CR87","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1161\/HYPERTENSIONAHA.109.135392","volume":"54","author":"T Nakamura","year":"2009","unstructured":"Nakamura, T. et al. Critical role of apoptosis signal-regulating kinase 1 in aldosterone\/salt-induced cardiac inflammation and fibrosis. Hypertension 54, 544\u2013551 (2009).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR88","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm1545","volume":"13","author":"JA Leopold","year":"2007","unstructured":"Leopold, J. A. et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat. Med. 13, 189\u2013197 (2007).","journal-title":"Nat. Med."},{"key":"BFnrneph201030_CR89","first-page":"597","volume":"17","author":"M Iglarz","year":"2004","unstructured":"Iglarz, M., Touyz, R. M., Viel, E. C., Amiri, F. & Schiffrin, E. L. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system. Am. J. Hypertens. 17, 597\u2013603 (2004).","journal-title":"Am. J. Hypertens."},{"key":"BFnrneph201030_CR90","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.bbrc.2003.11.173","volume":"313","author":"YM Park","year":"2004","unstructured":"Park, Y. M., Park, M. Y., Suh, Y. L. & Park, J. B. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem. Biophys. Res. Commun. 313, 812\u2013817 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrneph201030_CR91","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.107.109645","volume":"52","author":"L Michea","year":"2008","unstructured":"Michea, L. et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension 52, 295\u2013300 (2008).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR92","doi-asserted-by":"publisher","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","volume":"283","author":"R Rocha","year":"2002","unstructured":"Rocha, R. et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol 283, H1802\u2013H1810 (2002).","journal-title":"Am. J. Physiol. Heart Circ. Physiol"},{"key":"BFnrneph201030_CR93","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1210\/en.2002-220120","volume":"143","author":"R Rocha","year":"2002","unstructured":"Rocha, R. et al. Selective aldosterone blockade prevents angiotensin II\/salt-induced vascular inflammation in the rat heart. Endocrinology 143, 4828\u20134836 (2002).","journal-title":"Endocrinology"},{"key":"BFnrneph201030_CR94","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","volume":"54","author":"AJ Rickard","year":"2009","unstructured":"Rickard, A. J. et al. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54, 537\u2013543 (2009).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR95","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/01.RES.0000180753.63183.95","volume":"97","author":"LJ Min","year":"2005","unstructured":"Min, L. J. et al. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ. Res. 97, 434\u2013442 (2005).","journal-title":"Circ. Res."},{"key":"BFnrneph201030_CR96","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2353\/ajpath.2006.051351","volume":"169","author":"Y Nakamura","year":"2006","unstructured":"Nakamura, Y. et al. MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling. Am. J. Pathol. 169, 362\u2013371 (2006).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph201030_CR97","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1073\/pnas.0804037106","volume":"106","author":"Y Jeong","year":"2009","unstructured":"Jeong, Y. et al. Aldosterone activates endothelial exocytosis. Proc. Natl Acad. Sci. USA 106, 3782\u20133787 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph201030_CR98","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.amjhyper.2005.08.019","volume":"19","author":"J Irita","year":"2006","unstructured":"Irita, J. et al. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am. J. Hypertens. 19, 293\u2013297 (2006).","journal-title":"Am. J. Hypertens."},{"key":"BFnrneph201030_CR99","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/01.HYP.0000248135.97380.76","volume":"48","author":"JM Luther","year":"2006","unstructured":"Luther, J. M. et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 48, 1050\u20131057 (2006).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR100","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1161\/HYPERTENSIONAHA.107.103267","volume":"51","author":"C Savoia","year":"2008","unstructured":"Savoia, C., Touyz, R. M., Amiri, F. & Schiffrin, E. L. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 51, 432\u2013439 (2008).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR101","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1161\/01.HYP.33.4.981","volume":"33","author":"V Robert","year":"1999","unstructured":"Robert, V. et al. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 33, 981\u2013986 (1999).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR102","doi-asserted-by":"publisher","first-page":"V16","DOI":"10.1161\/01.HYP.5.6_Pt_3.V16","volume":"5","author":"EL Schiffrin","year":"1983","unstructured":"Schiffrin, E. L., Thom\u00e9, F. S. & Genest, J. Vascular angiotensin II receptors in renal and DOCA-salt hypertensive rats. Hypertension 5, V16\u2013V21 (1983).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR103","first-page":"H608","volume":"246","author":"EL Schiffrin","year":"1984","unstructured":"Schiffrin, E. L., Gutkowska, J. & Genest, J. Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am. J. Physiol. 246, H608\u2013H614 (1984).","journal-title":"Am. J. Physiol."},{"key":"BFnrneph201030_CR104","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1139\/y85-250","volume":"63","author":"EL Schiffrin","year":"1985","unstructured":"Schiffrin, E. L., Franks, D. J. & Gutkowska, J. Effect of aldosterone on vascular angiotensin II receptors in the rat. Can. J. Physiol. Pharmacol. 63, 1522\u20131527 (1985).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"BFnrneph201030_CR105","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1161\/CIRCRESAHA.109.196576","volume":"105","author":"CA Lemari\u00e9","year":"2009","unstructured":"Lemari\u00e9, C. A. et al. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ. Res. 105, 852\u2013859 (2009).","journal-title":"Circ. Res."},{"key":"BFnrneph201030_CR106","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cardiores.2007.07.008","volume":"76","author":"LJ Min","year":"2007","unstructured":"Min, L. J. et al. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc. Res. 76, 506\u2013516 (2007).","journal-title":"Cardiovasc. Res."},{"key":"BFnrneph201030_CR107","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1161\/ATVBAHA.108.168021","volume":"28","author":"AC Montezano","year":"2008","unstructured":"Montezano, A. C. et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler. Thromb. Vasc. Biol. 28, 1511\u20131518 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrneph201030_CR108","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/01.HYP.0000171479.36880.17","volume":"46","author":"J Blanco-Rivero","year":"2005","unstructured":"Blanco-Rivero, J. et al. Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. Hypertension 46, 107\u2013112 (2005).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR109","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1161\/HYPERTENSIONAHA.107.104299","volume":"51","author":"T Imanishi","year":"2008","unstructured":"Imanishi, T. et al. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension 51, 734\u2013741 (2008).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR110","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","volume":"105","author":"S Rajagopalan","year":"2002","unstructured":"Rajagopalan, S., Duquaine, D., King, S., Pitt, B. & Patel, P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105, 2212\u20132216 (2002).","journal-title":"Circulation"},{"key":"BFnrneph201030_CR111","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1161\/01.CIR.0000142858.44680.27","volume":"110","author":"A Garnier","year":"2004","unstructured":"Garnier, A. et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 110, 1819\u20131825 (2004).","journal-title":"Circulation"},{"key":"BFnrneph201030_CR112","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/bjp.2008.200","volume":"154","author":"FE Xavier","year":"2008","unstructured":"Xavier, F. E. et al. Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin. Br. J. Pharmacol. 154, 1225\u20131235 (2008).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrneph201030_CR113","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"Farquharson, C. A. & Struthers, A. D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation 101, 594\u2013597 (2000).","journal-title":"Circulation"},{"key":"BFnrneph201030_CR114","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1161\/01.HYP.0000049624.99844.3D","volume":"41","author":"X Peng","year":"2003","unstructured":"Peng, X., Haldar, S., Deshpande, S., Irani, K. & Kass, D. A. Wall stiffness suppresses Akt\/eNOS and cytoprotection in pulse-perfused endothelium. Hypertension 41, 378\u2013381 (2003).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR115","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/jbm.a.31112","volume":"81","author":"S Kidoaki","year":"2007","unstructured":"Kidoaki, S. & Matsuda, T. Shape-engineered vascular endothelial cells: nitric oxide production, cell elasticity, and actin cytoskeletal features. J. Biomed. Mater. Res. A 81, 728\u2013735 (2007).","journal-title":"J. Biomed. Mater. Res. A"},{"key":"BFnrneph201030_CR116","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1161\/01.HYP.0000123572.45556.a5","volume":"43","author":"H Oberleithner","year":"2004","unstructured":"Oberleithner, H. et al. Human endothelium: target for aldosterone. Hypertension 43, 952\u2013956 (2004).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR117","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/HJH.0b013e328013f492","volume":"25","author":"U Hillebrand","year":"2007","unstructured":"Hillebrand, U. et al. Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone. J. Hypertens. 25, 639\u2013647 (2007).","journal-title":"J. Hypertens."},{"key":"BFnrneph201030_CR118","doi-asserted-by":"publisher","first-page":"16281","DOI":"10.1073\/pnas.0707791104","volume":"104","author":"H Oberleithner","year":"2007","unstructured":"Oberleithner, H. et al. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc. Natl Acad. Sci. USA 104, 16281\u201316286 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph201030_CR119","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1291\/hypres.31.1811","volume":"31","author":"A Mutoh","year":"2008","unstructured":"Mutoh, A., Isshiki, M. & Fujita, T. Aldosterone enhances ligand-stimulated nitric oxide production in endothelial cells. Hypertens. Res. 31, 1811\u20131820 (2008).","journal-title":"Hypertens. Res."},{"key":"BFnrneph201030_CR120","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1161\/01.CIR.0000093188.53554.44","volume":"108","author":"SL Liu","year":"2003","unstructured":"Liu, S. L., Schmuck, S., Chorazcyzewski, J. Z., Gros, R. & Feldman, R. D. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108, 2400\u20132406 (2003).","journal-title":"Circulation"},{"key":"BFnrneph201030_CR121","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1161\/HYPERTENSIONAHA.107.088955","volume":"50","author":"F Nietlispach","year":"2007","unstructured":"Nietlispach, F. et al. Influence of acute and chronic mineralocorticoid excess on endothelial function in healthy men. Hypertension 50, 82\u201388 (2007).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR122","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1042\/cs1030425","volume":"103","author":"CA Farquharson","year":"2002","unstructured":"Farquharson, C. A. & Struthers, A. D. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin. Sci. (Lond.) 103, 425\u2013431 (2002).","journal-title":"Clin. Sci. (Lond.)"},{"key":"BFnrneph201030_CR123","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0021-9150(02)00363-5","volume":"166","author":"P Romagni","year":"2003","unstructured":"Romagni, P., Rossi, F., Guerrini, L., Quirini, C. & Santiemma, V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 166, 345\u2013349 (2003).","journal-title":"Atherosclerosis"},{"key":"BFnrneph201030_CR124","first-page":"3528","volume":"84","author":"BM Schmidt","year":"1999","unstructured":"Schmidt, B. M. et al. Short term cardiovascular effects of aldosterone in healthy male volunteers. J. Clin. Endocrinol. Metab. 84, 3528\u20133533 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph201030_CR125","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1161\/01.HYP.0000083298.23119.16","volume":"42","author":"BM Schmidt","year":"2003","unstructured":"Schmidt, B. M. et al. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 42, 156\u2013160 (2003).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR126","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1097\/01.ASN.0000083982.74108.54","volume":"14","author":"S Arima","year":"2003","unstructured":"Arima, S. et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J. Am. Soc. Nephrol. 14, 2255\u20132263 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201030_CR127","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1161\/01.RES.76.6.973","volume":"76","author":"M Wehling","year":"1995","unstructured":"Wehling, M., Neylon, C. B., Fullerton, M., Bobik, A. & Funder, J. W. Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells. Circ. Res. 76, 973\u2013979 (1995).","journal-title":"Circ. Res."},{"key":"BFnrneph201030_CR128","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1093\/ndt\/gfn118","volume":"23","author":"LA Cal\u00f2","year":"2008","unstructured":"Cal\u00f2, L. A. et al. Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways. Nephrol. Dial. Transplant. 23, 2804\u20132809 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201030_CR129","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1161\/01.HYP.0000128031.31572.a3","volume":"43","author":"DH Endemann","year":"2004","unstructured":"Endemann, D. H., Touyz, R. M., Iglarz, M., Savoia, C. & Schiffrin, E. L. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 43, 1252\u20131257 (2004).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR130","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/01.HYP.0000203772.78696.67","volume":"47","author":"K Nagata","year":"2006","unstructured":"Nagata, K. et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47, 656\u2013664 (2006).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR131","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","volume":"53","author":"JW Funder","year":"2009","unstructured":"Funder, J. W. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 53, 286\u2013290 (2009).","journal-title":"Hypertension"},{"key":"BFnrneph201030_CR132","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1210\/en.2004-0005","volume":"145","author":"M Young","year":"2004","unstructured":"Young, M. & Funder, J. W. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone\/salt-treated rats. Endocrinology 145, 3153\u20133157 (2004).","journal-title":"Endocrinology"},{"key":"BFnrneph201030_CR133","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1210\/en.2002-220926","volume":"144","author":"MJ Young","year":"2003","unstructured":"Young, M. J., Moussa, L., Dilley, R. & Funder, J. W. Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology 144, 1121\u20131125 (2003).","journal-title":"Endocrinology"},{"key":"BFnrneph201030_CR134","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1161\/01.CIR.0000030935.89559.04","volume":"106","author":"UP Jorde","year":"2002","unstructured":"Jorde, U. P. et al. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 106, 1055\u20131057 (2002).","journal-title":"Circulation"},{"key":"BFnrneph201030_CR135","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","volume":"119","author":"W Iraqi","year":"2009","unstructured":"Iraqi, W. et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 119, 2471\u20132479 (2009).","journal-title":"Circulation"},{"key":"BFnrneph201030_CR136","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","volume":"54","author":"NC Edwards","year":"2009","unstructured":"Edwards, N. C., Steeds, R. P., Stewart, P. M., Ferro, C. J. & Townend, J. N. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J. Am. Coll. Cardiol. 54, 505\u2013512 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrneph201030_CR137","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","volume":"118","author":"B Pitt","year":"2008","unstructured":"Pitt, B., Bakris, G., Ruilope, L. M., DiCarlo, L. & Mukherjee, R. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 118, 1643\u20131650 (2008).","journal-title":"Circulation"},{"key":"BFnrneph201030_CR138","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink, D. N. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543\u2013551 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201030_CR139","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.104.527549","volume":"112","author":"FA Masoudi","year":"2005","unstructured":"Masoudi, F. A. et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998\u20132001. Circulation 112, 39\u201347 (2005).","journal-title":"Circulation"},{"key":"BFnrneph201030_CR140","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0735-1097(02)02694-3","volume":"41","author":"B Bozkurt","year":"2003","unstructured":"Bozkurt, B., Agoston, I. & Knowlton, A. A. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J. Am. Coll. Cardiol. 41, 211\u2013214 (2003).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrneph201030_CR141","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/ki.2009.9","volume":"75","author":"WB Lea","year":"2009","unstructured":"Lea, W. B. et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 75, 936\u2013944 (2009).","journal-title":"Kidney Int."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.30.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.30","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.30.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:34:06Z","timestamp":1684456446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2010.30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,16]]},"references-count":141,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["BFnrneph201030"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2010.30","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,16]]}}}